Serina Therapeutics, Inc. (SER): debt financing — AgeX draws remaining $500K under Secured Note, reaches $13.16M max; issues 340K warrants at $0.735

Serina Therapeutics, Inc.

Borrowed final $500,000 on Jan 25, 2023, reaching the $13,160,000 maximum principal under the Secured Convertible Note with Juvenescence.
Outstanding principal due Feb 14, 2024; interest replaced by Origination Fee of 4% per draw plus additional 4% after 12-month draw period.
Will issue warrants for 340,136 shares of common stock at $0.735 per share to Juvenescence, subject to NYSE American listing approval.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited at 4% of the amount each draw of loan funds maturing February 14, 2024.

Instrument: convertible notes
Principal: $500,000
Counterparty: Juvenescence Limited
Rate: 4% of the amount each draw of loan funds
Maturity: February 14, 2024
Event: incurrence

Exact text from the filing

On January 25, 2023, AgeX borrowed the remaining $500,000 under the Secured Convertible Promissory Note (the “Secured Note”) dated as of February 14, 2022 with Juvenescence Limited (“Juvenescence”).

View on SEC.gov

89 debt financings filed in the last 30 days. Browse all debt financings →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-002757

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.